All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
2 warning events since 2021; the latest 2025-08-05.
From the record
ImageneBio, Inc.'s filings since 2021 show 2 warning events of 2 kinds: a notice about its exchange listing (8-K item 3.01, the latest 2023-06-30); an auditor change (8-K item 4.01, the latest 2025-08-05) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
-38.6% a year over 6 filed years; profitable in 0 of 6.
From the record
ImageneBio, Inc.'s 6 filed years say what it did: revenue went from $9 million in fiscal 2020 to $800 thousand in fiscal 2025, down 38.6% a year; it rose in 1 of 5 years; the deepest fall was 97% from fiscal 2021 to fiscal 2025; net income was positive in 0 of 6 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 10.0/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: ImageneBio, Inc.'s shareholder treatment is put at 10.0 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 1% of 146 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -34%: lost 34¢ per shareholder dollar. Leverage 13%: owes 13¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, ImageneBio, Inc. lost about 34 cents for every dollar of shareholders' money. Leverage: it owed about 13 cents per dollar of assets, and net share issuance: its share count grew 307.9% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
bottom 13% of 102 in its family; net margin -5668.6%.
From the record
ImageneBio, Inc.'s standing among 102 graded names in its industry family: revenue of $800 thousand in fiscal 2025 ranks in the bottom 17% by size; a net margin of -5668.6% ranks in the bottom 19%; revenue growth of -62.9% a year over the last 3 filed years ranks in the bottom 4% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
SI estimate 0.1/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: ImageneBio, Inc.'s leadership is put at 0.1 of 10 with a confidence of 35 of 100, because read from one part only, officer and director changes on Form 8-K over three years, against the people in charge, which ranks in the bottom 1% of 137 in its family; the record of its people begins on 2025-07-25 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 1.3 years and cannot see past it; a floor under five years is not read as years in charge. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they set up to do next?
How much room does it have to grow?
top 41% of 92 in its family for room to expand.
From the record
ImageneBio, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $95 million against no long-term debt tagged leaves 61.8% of its assets as net cash, top 24% of its family; cash from operations less capital spending is -5980.5% of revenue (bottom 14%); research spending of 3565.6% of revenue (top 13%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
bottom 25% of 100 in its family for growth drivers.
From the record
ImageneBio, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew -62.9% a year over the last three filed years against -38.6% over all 6, slowing (bottom 28% of its family); the newest year grew -77.2% (bottom 3%); research spending grew -23.7% a year (bottom 9%); capital spending grew -18.6% a year (top 39%) (its annual reports). ImageneBio, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
bottom 26% of 72 in its family for expectations against reality.
From the record
ImageneBio, Inc.'s newest year against its own record: revenue of $800 thousand in fiscal 2025 came in 51.7% below the $2 million its prior three years' pace pointed to (bottom 15% of its family); net income of $45 million against a prior three-year average of $58 million (top 43%); a net margin of a loss larger than its revenue against losses larger than its revenue before (bottom 6%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made